Latest filing published 12 Aug 2025 for Hansa Biopharma AB, €47k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Peter Nicklin: trading record in brief
Peter Nicklin discloses dealings in Hansa Biopharma AB to Finansinspektionen. In total, 4 filings cover trades dated from 19 July 2022 to 5 August 2025.
No open-market sale appears; the market trades are 4 purchases worth €278k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2025: 1 purchase and no sales on the market.
In size, the median ticket on the buying side is €73k.
The newest entry dates from 12 August 2025: an open-market purchase of €47k, in Hansa Biopharma AB. Typically, a trade is published a median of 7 days after it takes place. For comparison, MAR article 19 gives managers three business days to notify a trade. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Companies and markets linked to Peter Nicklin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 17,067 shares@ SEK 30.64AktieISIN SE0002148817FI:csv-d64a5298f04da9920abaCanonical exit: 3 Nov 2025 (T+90)
- 10,000 shares@ SEK 38.8825.7% of flowAktieISIN SE0002148817FI:csv-ee54c4efab6889c09a5dCanonical exit: 6 May 2024 (T+90)
- 14,500 shares@ SEK 71.1857100.0% of flowAktieISIN SE0002148817FI:csv-943bc78abf2b1638d767Canonical exit: 17 Oct 2022 (T+90)
3 of 3 declarations